INDV
$31.33
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Can...
Recent News
How Indivior’s Upsized $450 Million Convertible Notes and Buybacks May Impact Indivior (INDV) Investors
In March 2026, Indivior Pharmaceuticals, Inc. completed an upsized private offering of US$450,000,000 in 0.625% convertible senior unsecured notes due March 15, 2031, using the proceeds to repay existing credit facilities, repurchase about 2,400,000 shares, and fund general corporate purposes. Alongside this financing move, stronger-than-expected 2025 earnings and recent insider share purchases have highlighted improving operations and management confidence in the business. Next, we’ll...
Implied Volatility Surging for Indivior Pharmaceuticals Stock Options
Investors need to pay close attention to INDV stock based on the movements in the options market lately.
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Recent Name Change
What just happened with Indivior Pharmaceuticals Indivior Pharmaceuticals (INDV) has drawn fresh attention after recently changing its name from Indivior PLC to Indivior Pharmaceuticals, Inc., a shift that puts its US operations and buprenorphine based treatment portfolio in clearer focus for investors. See our latest analysis for Indivior Pharmaceuticals. While the recent name change has sharpened the focus on its prescription treatment portfolio, Indivior Pharmaceuticals’ 1-year total...
Indivior PLC Q4 2025 Earnings Call Summary
Moby summary of Indivior PLC's Q4 2025 earnings call
Indivior Q4 Earnings Call Highlights
Indivior (NASDAQ:INDV) executives told investors the company’s 2025 performance reflected a “transition year” marked by progress on its “Indivior Action Agenda,” while setting expectations for faster growth and improved profitability in 2026 driven primarily by SUBLOCADE. 2025 results and progress